Side-by-side financials for CMMB and LLY. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CMMB | LLY |
|---|---|---|
| Market cap | - | $1.093 T |
| US-listed rank | - | #11 |
| Revenue (latest FY) | - | $65.18B |
| Net income (latest FY) | -$8.99M | $20.64B |
| Net margin | - | 31.7% |
| P/E (trailing FY) | - | 53.0 |
| SEC filings | 347 | 989 |
Full pages: Chemomab Therapeutics Ltd. and ELI LILLY & Co, or browse the full rankings.